6533b872fe1ef96bd12d3836
RESEARCH PRODUCT
Adult Coats’ Disease Successfully Managed with the Dexamethasone Intravitreal Implant (Ozurdex®) Combined with Retinal Photocoagulation
Manuel Díaz-llopisCristina Marín-lambíesRosa Dolz-marcoSebastián Martínez-castilloRoberto Gallego-pinazosubject
medicine.medical_specialtyRetinal vasoproliferative tumorVisual acuitychemistry.chemical_compoundRetinal telangiectasislcsh:OphthalmologyOphthalmologymedicineDexamethasone Intravitreal ImplantDexamethasone intravitreal implant (Ozurdex®)Coats' diseaseCoats’ diseaseDexamethasoneRetinabusiness.industryRetinalmedicine.diseaseSurgeryOphthalmologymedicine.anatomical_structurechemistrylcsh:RE1-994Published: March 2012Retinal TelangiectasisImplantmedicine.symptombusinessmedicine.drugdescription
Purpose: To report a case of Coats’ disease managed with the dexamethasone intravitreal implant Ozurdex® (Allergan, Inc., Irvine, Calif., USA) combined with retinal photocoagulation. Methods: A 46-year-old female with 20/200 visual acuity was diagnosed with Coats’ disease with secondary retinal vasoproliferative tumor. An initial approach was performed with an intravitreal injection of the sustained-release dexamethasone implant Ozurdex. After reattachment of the retina, the telangiectatic vessels were treated with laser photocoagulation. Results: The patient’s visual acuity improved to 20/25 after the intravitreal Ozurdex. No further recurrences of exudation were evident through the 12-month follow-up. Conclusions: Ozurdex may be an effective initial therapeutic approach for Coats’ disease with immediate anatomical response and visual improvement.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-03-01 | Case Reports in Ophthalmology |